Awadhesh Kumar Singh
Overview
Explore the profile of Awadhesh Kumar Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
2967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh A, Singh A, Singh R, Misra A
Diabetes Metab Syndr
. 2025 Mar;
19(3):103212.
PMID: 40086043
Background And Aims: Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of...
2.
Singh A, Singh A, Singh R
Expert Opin Pharmacother
. 2025 Feb;
:1-16.
PMID: 39918955
Introduction: Major global guidelines currently recommend sodium-glucose co-transporter-2 inhibitors (SGLT-2i) as the first-line agent in people with type 2 diabetes (T2D) who have either established cardiovascular disease (eCVD), heart failure...
3.
Singh A, Das A, Murthy L, Ghosal S, Sahay R, Harikumar K, et al.
Adv Ther
. 2024 Dec;
42(2):801-812.
PMID: 39636567
Introduction: A slower adoption rate of fixed dose combinations (FDC) in diabetes management is partly due to insufficient data. This study evaluates the safety and efficacy of an FDC of...
4.
Singh A, Chatterjee S, Singh A, Bhattacharjee R
Indian J Endocrinol Metab
. 2024 Oct;
28(4):378-384.
PMID: 39371648
Physicians and endocrinologists commonly face various questions related to dietary interventions during clinical encounters with their patients with thyroid disorders. Indeed, both patients and treating physicians have various misconceptions regarding...
5.
Singh A, Kesavadev J, Tiwaskar M
J Assoc Physicians India
. 2024 Aug;
72(8):11-12.
PMID: 39163055
Nonarteritic anterior ischemic optic neuropathy (NAION) was first documented by a French physician Jean-Pierre Saint-Yves in 1817 (19th century). The clinical description of NAION was not known until 1935 when...
6.
Prasanna Kumar K, Chowdhury S, Bantwal G, Unnikrishnan A, Kalra S, Aggarwal S, et al.
Cureus
. 2024 Jun;
16(5):e60983.
PMID: 38910730
Achieving and maintaining optimal glycemic targets is the fundamental goal of the management of diabetes. However, failure of oral antidiabetic drugs (OADs) to sustain the targeted glycemic levels in individuals...
7.
Singh A, Misra A, Das A, Behl A, Srivastava A, Paneerselvam A, et al.
J Assoc Physicians India
. 2024 May;
71(12):62-74.
PMID: 38736056
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been used for almost a decade and have proven to be effective not only in managing Type 2 diabetes (T2D), but their cardio and...
8.
Mohan V, Misra A, Bhansali A, Singh A, Makkar B, Krishnan D, et al.
J Assoc Physicians India
. 2024 May;
71(12):36-46.
PMID: 38736053
Background: Obesity, prediabetes, and type 2 diabetes mellitus (T2DM) pose a triple burden in India. Almost two-thirds of people with diabetes (PWD) in India are found to have suboptimal glycemic,...
9.
Singh A, Singh R, Singh A, Misra A
Diabetes Metab Syndr
. 2024 May;
18(5):103024.
PMID: 38718449
Background And Aims: Oral semaglutide has undergone global Phase 3 development programs named PIONEER and approved for therapeutic use in people with type 2 diabetes (T2D). We aim to systematically...
10.
Ray S, Kapoor N, Deshpande N, Chatterjee S, Kumar J, Tantia O, et al.
Expert Rev Clin Pharmacol
. 2024 Mar;
17(4):349-362.
PMID: 38471973
Introduction: With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in...